CD133 Is a Useful Surrogate Marker for Predicting Chemosensitivity to Neoadjuvant Chemotherapy in Breast Cancer

BACKGROUND: Neoadjuvant chemotherapy (NAC) is a standard care regimen for patients with breast cancer. However, the pathologic complete response (pCR) rate remains at 30%. We hypothesized that a cancer stem cell marker may identify NAC-resistant patients, and evaluated CD133 and ALDH1 as a potential...

Descripción completa

Detalles Bibliográficos
Autores principales: Aomatsu, Naoki, Yashiro, Masakazu, Kashiwagi, Shinichiro, Takashima, Tsutomu, Ishikawa, Tetsuro, Ohsawa, Masahiko, Wakasa, Kenichi, Hirakawa, Kosei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3457956/
https://www.ncbi.nlm.nih.gov/pubmed/23049880
http://dx.doi.org/10.1371/journal.pone.0045865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3457956/
https://www.ncbi.nlm.nih.gov/pubmed/23049880
http://dx.doi.org/10.1371/journal.pone.0045865

Ejemplares similares